In 2016, it was estimated that more than 15.5 million cancer survivors were living in the US, and this number will increase to more than 20 million by 2026. Highly effective treatments have been developed, and the increase in survival demands more attention to patient’s quality of life and management of adverse effects. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of various cancer therapies, such as paclitaxel and cisplatin. CIPN is one of the most challenging pain conditions with poor response to pharmacotherapy; therefore, discontinuation of chemotherapy or dose reduction often remains the only clinical solution.
The thesis focused on using quantitative approach for improving our understanding of the relationships between tissue distribution of the chemotherapeutic agents and CIPN development. In an introductory Chapter 1, an overview of the chemotherapeutics, CIPN, formulations, and modeling approaches is presented. In Chapter 2, a physiologically-based pharmacokinetic (PBPK) model was developed to characterize the whole-body disposition of paclitaxel following administration of a commercially available formulation (Taxol®). Pharmacokinetic data of paclitaxel in mice from multiple publications was collected and used for model development. Interspecies scaling approaches were incorporated in the model and provided reasonable prediction of tissue disposition of paclitaxel in rats and plasma pharmacokinetics in humans. In Chapter 3, a nanoparticle formulation of paclitaxel was developed. The neurotoxicity development in rats was significantly reduced after administration of the PEGylated liposomal paclitaxel compared to Taxol®. The formulation has also significantly altered paclitaxel disposition into tissues. In Chapter 4, a quantitative relationship between the dose, plasma pharmacokinetics, and paclitaxel-induced peripheral neurotoxicity was established by evaluating the paw withdrawal threshold to mechanical stimuli after intravenous administration of Taxol® to rats using experimental data and published literature. Indirect response models adequately described the pharmacokinetic-pharmacodynamic relationship. In Chapter 5, a PBPK model of cisplatin (another neurotoxic compound) was developed based on multiple published data sets from preclinical species. The model included the uncommon metabolism and binding pattern of cisplatin, and an interspecies scaling approach based on protein turnover rate was developed. The model successfully predicted cisplatin pharmacokinetics in humans. Collectively, the studies provided important insights into quantitative relationships for neurotoxic chemotherapeutics. Translational PBPK and PK-PD modeling approaches can be further utilized for optimization of therapy with neurotoxic chemotherapeutics.
Subject (authority = RUETD)
Topic
Pharmaceutical Science
Subject (authority = ETD-LCSH)
Topic
Chemotherapy--Side effects
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Identifier (type = RULIB)
ETD
Identifier
ETD_9383
PhysicalDescription
Form (authority = gmd)
electronic resource
InternetMediaType
application/pdf
InternetMediaType
text/xml
Extent
1 online resource (182 pages) : illustrations
Note (type = degree)
Ph.D.
Note (type = bibliography)
Includes bibliographical references
Note (type = statement of responsibility)
by Xiaowei Zang
RelatedItem (type = host)
TitleInfo
Title
School of Graduate Studies Electronic Theses and Dissertations
Identifier (type = local)
rucore10001600001
Location
PhysicalLocation (authority = marcorg); (displayLabel = Rutgers, The State University of New Jersey)
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.